All In Biotech

Drug Trial Radar · NCT04929483

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

222

Actual

Start

Jun 4, 2021

Primary completion

Feb 14, 2023

Study completion Oct 8, 2024

Sponsor

Lead sponsor
89bio, Inc.Industry
Sponsor type
Industry
First posted
Jun 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

  • BIO89-100Drug

    Subcutaneous injection

  • PlaceboDrug

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of FibrosisTime frame: Week 24
  2. Main Study: Number of Participants Who Achieved Improvement of Fibrosis ≥1 Stage Without Worsening of NASHTime frame: Week 24

Locations

89 sites in 2 countries. Site status is shown where the registry gives one.

  • 89bio Clinical Study Site

    Birmingham, Alabama

  • 89bio Clinical Study Site

    Birmingham, Alabama

  • 89bio Clinical Study Site

    Dothan, Alabama

  • 89bio Clinical Study Site

    Guntersville, Alabama

  • 89bio Clinical Study Site

    Madison, Alabama

  • 89bio Clinical Study Site

    Chandler, Arizona

  • 89bio Clinical Study Site

    Glendale, Arizona

  • 89bio Clinical Study Site

    Peoria, Arizona

  • 89bio Clinical Study Site

    Tucson, Arizona

  • 89bio Clinical Study Site

    Tucson, Arizona

  • 89bio Clinical Study Site

    Tucson, Arizona

  • 89bio Clinical Study Site

    Little Rock, Arkansas

  • 89bio Clinical Study Site

    Little Rock, Arkansas

  • 89bio Clinical Study Site

    Chula Vista, California

  • 89bio Clinical Study Site

    Huntington Park, California

  • 89bio Clinical Study Site

    Long Beach, California

  • 89bio Clinical Study Site

    Orange, California

  • 89bio Clinical Study Site

    Panorama City, California

  • 89bio Clinical Study Site

    Rialto, California

  • 89bio Clinical Study Site

    Santa Ana, California

  • 89bio Clinical Study Site

    Englewood, Colorado

  • 89bio Clinical Study Site

    Boynton Beach, Florida

  • 89bio Clinical Study Site

    Bradenton, Florida

  • 89bio Clinical Study Site

    Fort Myers, Florida

  • 89bio Clinical Study Site

    Lakeland, Florida

  • 89bio Clinical Study Site

    Maitland, Florida

  • 89bio Clinical Study Site

    Miami, Florida

  • 89bio Clinical Study Site

    Miami, Florida

  • 89bio Clinical Study Site

    Miami, Florida

  • 89bio Clinical Study Site

    Miami Lakes, Florida

  • 89bio Clinical Study Site

    Ocala, Florida

  • 89bio Clinical Study Site

    Palmetto Bay, Florida

  • 89bio Clinical Study Site

    Pinellas Park, Florida

  • 89bio Clinical Study Site

    Port Orange, Florida

  • 89bio Clinical Study Site

    Sarasota, Florida

  • 89bio Clinical Study Site

    Viera, Florida

  • 89bio Clinical Study Site

    Athens, Georgia

  • 89bio Clinical Study Site

    Sandy Springs, Georgia

  • 89bio Clinical Study Site

    New Albany, Indiana

  • 89bio Clinical Study Site

    South Bend, Indiana

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.